The crizotinib-coated pellet product is approved in the US for the treatment of relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) and unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive. The gene discussed is ALK; the disease is inflammatory myofibroblastic tumor.